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ABSTRACT 
 
Great interest is shown by researchers to functional and rheological features of basic regular blood 
elements. Platelets are among them and take the most active part in hemostasis at rather wide-
spread nowadays cardio-vascular and metabolic diseases. The aim is to analyze dynamics’ 
strengthening of platelets' intravascular activity of rats in conditions of experimental consequent 
development of arterial hypertension and dyslipidemia. The study used 68 male-rats of Vistar line at 
the age of 2.5-3 months. Control group was composed of 33 animals. Experimental animals (35 
rats) were developed at first – arterial hypertension (usage of cardioangiol pathogenic diet for 2 
weeks and impact of cold at the end) and then - dyslipidemia (application of rich in calories diet at 
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lowering of motor activity). The rats from experimental group were examined 5 times during the 
research. The rats from control group were examined twice - at the beginning and at the end of the 
experiment. While examining experimental and control rats we applied biochemical, hematological 
and statistical methods of investigation. At consequent arterial hypertension and dyslipidemia 
development experimental rats had gradual strengthening of lipids' peroxidation processes in 
plasma (acylhydroperoxides increased in 2.1 times) and platelets (acyl hydroperoxides increased in 
1.4 times). Already at arterial hypertension development rats' blood was noted to have lowering of 
discocytes' quantity on 5.9%, deepening during the further dyslipidemia development on 7.4% more, 
and reaching 24.6±0.13%. This process was accompanied by gradual increase of activated 
platelets' sum on 75.7% during the whole period of investigation. The number of small, middle and 
large platelet aggregates, freely circulating in blood during modeling of double pathology, gradually 
increased in 2.8 times and in 10.3 times, respectively. Control rats had stable normal level of 
relevant biochemical and hematological characteristics. Subsequent development of at first arterial 
hypertension and then – dyslipidemia in rats gradually weakened their antioxidant protection of 
blood plasma and platelets and strengthened POL processes in them. It also strengthened lipids' 
peroxidation in them. Developing abnormalities gradually strengthened intravascular platelets' 
activity and their aggregative ability in experimental animals. The created model allowed tracking the 
earliest symptoms of strengthening of platelets’ intravascular activity against the background of AH 
and dyslipidemia development.  
 
 
Keywords: Rats; platelets; intravascular activity; model of arterial hypertension and dyslipidemia. 
 
1. INTRODUCTION 
 
At present medicine devotes special attention to 
early stages of pathology development and 
mechanisms providing this development [1,2]. 
Great interest is shown by researchers to 
functional and rheological features of basic 
regular blood elements [3,4,5]. Platelets are 
among them and take the most active part in 
hemostasis at rather wide-spread cardio-vascular 
and metabolic diseases [6,7]. One of the leading 
positions among them in the whole civilized world 
is occupied by arterial hypertension (AH) leading 
to wide incapacitation of population and 
significantly contributing mortality of persons able 
to work [8,9]. Different metabolic abnormalities 
are developed more and more often against the 
background of AH. One of leading places among 
them belongs to dyslipidemia. It rather negatively 
influences the common prognosis [10,11]. It was 
noticed earlier that at long AH clinical course, 
especially loaded by metabolic abnormalities, 
patients had rising platelets aggregative activity 
[12] and lowering dis aggregative vessels' activity 
[13]. It essentially activated hemostasis and 
additionally worsened microcirculation and 
metabolic processes in all the tissues [14,15]. At 
the same time, platelets' intravascular activity at 
initial stages of AH development in combination 
with dyslipidemia has not yet been fully studied. 
 
It is rather difficult to track on a human being the 
earliest stages of intravascular platelets' activity 
rise at the first AH manifestations and developing 
against its background dyslipidemia because 
such patients very rarely turn for medical 
treatment. It dictated the necessity of 
investigations on laboratory animals [16] with 
developing of at first AH and then – dyslipidemia 
in them. The researches, which were conducted 
earlier, studied development of AH [17,18] and 
dyslipidemia [19,20] on the models of animals. 
The researchers estimated different aspects of 
their pathogenesis [21,22]. At the same time, 
estimation of the earliest manifestations of 
platelets’ intravascular activity increase in the 
model of consequent development of AH and 
dyslipidemia, hasn’t yet been studied. In this 
connection we put the aim: to estimate the 
dynamics of strengthening of intravascular 
platelets' activity of rats in conditions of 
experimental consequent arterial hypertension 
and dyslipidemia development. 
 
2. MATERIALS AND METHODS 
 
2.1 Materials 
 
Our research was conducted in accordance with 
ethical principles established by the European 
Convent on protection of vertebrates which are 
used for experimental and other scientific 
purposes (adopted in Strasbourg 18.03.1986 and 
ratified in Strasbourg 15.06.2006). The research 
was approved by the Ethics Committee of Kursk 
Institute of Social Education (a branch of Russian 
State Social University) (record №5 from 
12.05.2014) and All-Russian Research Institute 
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of Physiology, Biochemistry and Nutrition of 
Animals (record №6 from 05.06.2014). Ethics 
Committees ratified the need to use animals for 
the study, sufficiency of animals’ number in the 
study and humanity and minimum of impact on 
animals during the experiment.  
 
The study used 68 healthy male-rats of Vistar 
line at the age of 2.5-3 months got from healthy 
females by first or second brood. 33 animals of 
them were fed with combined feed by 
"Laboratorkorm" production (Russia) in corpore, 
were exposed to nothing and composed control 
group. They were examined twice: At the 
beginning and at the age of 4-4.5 months, i.e. 
simultaneously with the completion of 
experimental rats’ observation. There were no 
statistically significant differences between the 
results of both studies. That’s why, received data 
are presented by one figure - their arithmetic 
average. 35 rats were to have arterial 
hypertension after feeding with cardio 
angionepho-pathogenic semi synthetic diet for 2 
weeks. This diet was enriched by cholesterol, 
filled by salts of twice-substituted phosphate 
aqueous natrium and scarce in potassium and 
magnesium suspension of hydrocortisone 
acetate. This preparation was injected 
intramuscularly daily by 1.5 mg on each 100 gr of 
animal's body mass. Water for drinking was 
substituted by 1% dilution of common salt. The 
animals were also exposed to cold - at the end of 
the given 2weeks' impact - 4ºC for 4 hours [23]. 
In three days after AH development these rats 
were put into small cages (a rat in a cage) for 30 
days. They began to be fed with high-calorific 
diet consisting of combined feed (47%), sweet 
condensed milk (44%), vegetable oil (8%) and 
vegetable starch (1%). So, they got lipids- 
29.6%, proteins- 14.8%, carbohydrates- 55.6% 
[24] in their ration. 
 
Experimental rats were examined five times - at 
the beginning, at the end of AH formation, in 3 
days after AH modeling (at the beginning of 
additional dyslipidemia development), in 15 days 
after the beginning of dyslipidemia development 
and at the end of its experimental development. 
 
2.2 Methods 
 
Measurements of animals’ arterial pressure (AP) 
were carried out noninvasively with the help of 
the device MLU/4c501 by the method of tail cuff 
superposition (MedLab, China). The level of 
lipids' peroxidation (POL) in animals' plasma was 
determined according to the quantity of existing 
thiobarbituric acid (TBA)-active products in it with 
the help of the set "Agat-Med" (Russia) and 
according to the contents of acylhydroperoxides 
(AHP), taking into consideration the level                    
of antioxidant activity of the blood liquid part   
[25]. 
 
Concentrations of common cholesterol (CCS) 
and triglycerides (TG) in animals’ blood were 
determined by enzymatic colorimetric method 
with application of a set produced by “Vital 
Diagnostikum”. The content of high-density 
lipoproteins (HDLP) in plasma CS was 
determined by a set produced by “Olveks 
Diagnostikum,” again by enzymatic colorimetric 
method. The CS content of low-density 
lipoproteins (LDLP) was determined using the 
formula reported by W. Friedwald et al. (1972). 
Concentration of CS in very low-density 
lipoproteins (VLDLP) was calculated according to 
the formula: CS VLDLP = concentration     
TG/2.2. 
 
We determined the concentration of 
malondialdehyde (MDA) and AHP and also the 
activity of catalase and superoxide dismutase 
(SOD) in platelets [19]. We also estimated 
enzymatically the level of cholesterol in platelets 
with the help of the set "Vital Diagnostikum" 
(Russia) and found the concentration of common 
phospholipids (CPL) [25]. We carried out 
washing platelets off plasma for estimation of 
POL products’ content in platelets, level of lipids 
and antioxidant activity of enzymes. It was done 
according to the following method. Blood, mixed 
with 5% ethylene-diamine-tetra-acetic acid, was 
centrifuged at 1000 turns a minute during 10 
minutes. Supernatant layer was put into clean 
dry test tube and centrifuged at 1500 turns a 
minute for 6 minutes. Then, the same layer was 
put into new clean dry test tube and centrifuged 
at 2200 turns a minute for 15 minutes. In the 
result, we got precipitation which was composed 
only of platelets. Then, supernatant liquid was 
removed, and there was added 1/3 of the volume 
of initial blood of 0.85% sodium chloride solution 
to the platelets’ precipitation. It was prepared on 
2.7% solution of ethylene-diamine-tetra-acetic 
acid. The precipitation was mixed carefully and 
centrifuged at 2200 turns a minute for 10 
minutes. After that, the supernatant was 
removed, and there was again added 
physiological solution to the precipitation which 
was prepared on the solution of ethylene-
diamine-tetra-acetic acid. The described 
procedure was conducted three times [26].  
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Statistical processing of received data was made 
with the help of a programme package “Statistics 
for Windows v. 6.0”, “Microsoft Excel”. 
Differences in data were considered reliable in 
case of р<0.05. 
  
The quantity of platelets in blood was calculated 
in Gorjaev's box. The morphology of 
intravascular platelets' activity was determined 
with the help of phase-contrast microscope [27]. 
The results were processed by Student's 
criterion (t).  
 
3. RESULTS AND DISCUSSION 
 
Experimental rats had stable increase of systolic 
and diastolic AP levels after AH development. 
They still had it against the background of 
dyslipidemia development till the end of 
investigation (Table 1). 
 
Rats with AH were noted to have increased AHP 
and TBA-active products' quantity in plasma. At 
dyslipidemia development AHP and TBA-active 
products' concentrations in plasma additionally 
increased in these animals, becoming essentially 
higher than control figures. Found POL 
strengthening at consequent modeling of AH    
and dyslipidemia in rats was possible because    
of gradual weakening of antioxidant            
plasma activity in them summarily on 43.8% 
(Table 1). 
 
At AH development the quantity of cholesterol 
rose a bit in rats’ platelets while the content of 
common phospholipids in their membranes 
stayed stable at the given stage. During 
dyslipidemia development cholesterol rose in 
them, but common phospholipids lowered    
(Table 2).  
 
During AH development POL activated in rats’ 
platelets on behalf of activity weakening of their 
antioxidant protection. Given changes were 
evidently strengthened during consequent 
dyslipidemia development. It provided summary 
growth of AHP and MDA in platelets on 36.8% 
and 54.3%, respectively. Observed changes of 
POL activity in platelets of model animals at AH 
and dyslipidemia development were possible as 
the result of their catalase and superoxide 
dismutase summary depression on 27.2% and 
13.0%, respectively (Table 2). 
 
There was reached lowering of discocytes' 
quantity in rats’ blood on 6.2% already at AH 
development. It deepened on 7.4% against the 
background of further dyslipidemia development. 
It was accompanied by gradual rise of activated 
platelets' sum on 75.7% on behalf of smooth 
increase of all their varieties (disco-echinocytes, 
spherocytes, sphero-echinocytes and bipolar 
forms) during the whole period of investigation. 
The number of small, middle and large platelet 
aggregates freely circulating in blood, while 
modeling of double pathology, gradually 
increased in 2.8 times and in 10.3 times, 
respectively (Table 2). 
 
In conducted experiment on consequent AH and 
then - dyslipidemia development in rats we 
observed rather relevant for a human being [28] 
weakening of antioxidant plasma potential which 
led to gradual increase of AHP and TBA-active 
compounds' quantity in it. Developing activation 
of POL processes in plasma caused surface 
structures' alteration of regular blood elements 
[29] in animals, including platelets. It promoted 
early increase of their activity [30]. 
 
Forming changes in model rats in ratio between 
lipids' fractions of platelets' membranes and POL 
activation in them early damaged receptor and 
post-receptor mechanisms of their functioning. 
Observed lipid membrane imbalance led to 
abnormal dynamics of platelet ion and 
antioxidant regulation [31]. It provided negative 
changes in their metabolism and activity rise in 
vessels' lumen what was rather relevant for 
patients with AH [32]. 
 
Observed increase of intravascular platelets' 
activity in experimental rats pointed indirectly at 
the rise of inductors' aggregation level (thrombin, 
ADF, adrenaline) in their blood while AH and 
then - dyslipidemia development. At the same 
time, platelets' sensitivity to them increased [33]. 
On this reason there began to develop reliable 
lowering of discoid platelets' quantity in blood of 
experimental rats. It supported activity increase 
of their receptors [34]. Number increase of 
platelets' active forms in these animals' blood 
during the experiment coincided with the 
increase of their aggregative activity and was 
connected, first of all, with expression 
strengthening of fibrinogenic receptors (GP IIb - 
IIIa) on their membranes [35]. It's evident that in 
experimental rats it was accompanied by gradual 
density increase of platelet glycoproteins Ia-IIa, 
Ib and VI, availability rise of vascular wall's 
collagen and level increase of von Willebrand 
Factor in plasma [36]. 
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Table 1. Dynamics of blood pressure and biochemical plasma parameters in experimental rats 
 
Registered 
parameters 
Experimental formation of AH, M±m, 
n=35 
Experimental formation of dyslipidemia against the 
background of AH, M±m, n=35 
Control, M±m, 
n=33 
Initial stage End of AH 
formation 
Initial stage Intermediate stage End of 
dislipidemia 
formation against 
the background of 
AH 
 
systolic blood pressure, mm et.al. Hg. 110.4±0.23 152.6±0.41 р<0.01 152.0±0.39 р<0.01 149.9±0.51 р<0.01 152.4±0.51 р<0.01 110.5±0.33 
Diastolic blood pressure, mm et.al. Hg. 74.2±0.32 94.8±0.33 р<0.01 95.1±0.28 р<0.01 94.6±0.39 р<0.01 95.2±0.42 р<0.01 73.6±0.40 
Total cholesterol, mmol / l 2.18±0.007 2.20±0.009 2.21±0.01 2.50±0.010 р<0.01 2.82±0.011 р<0.01 2.19±0.008 
HDL cholesterol, mmol / l 1.14±0.009 1.13±0.011 1.16±0.012 1.00±0.010 р<0.05 0.89±0.016 р<0.01 1.17±0.005 
LDL cholesterol, mmol /l 0.56±0.008 0.58±0.007 0.57±0.005 0.88±0.009 р<0.01 1.12±0.011 р<0.01 0.55±0.002 
VLDL, mmol /l 0.48±0.006 0.49±0.009 0.48±0.005 0.62±0.008 р<0.01 0.81±0.006 р<0.01 0.47±0.005 
TG, mmol /l 1.06±0.009 1.08±0.009 1.07±0.004 1.38±0.009 р<0.01 1.79±0.010 р<0.01 1.05±0.004 
AHP, D233 /1ml   1.35±0.007 1.74±0.006 р<0.01 1.78±0.005 р<0.01 2.36±0.009 р<0.01 2.85±0.012 р<0.01 1.38±0.004 
TBA-compounds, umol/l  2.15±0.009 2.91±0.007 р<0.01 2.94±0.008 р<0.01 3.41±0.016 р<0.01 4.20±0.014 р<0.01 2.12±0.008 
antioxidant activity, % 28.9±0.15 24.7±0.09 р<0.05 24.8±0.13 р<0.05 22.3±0.10 р<0.01 20.1±0.09 р<0.01 29.0±0.10 
Conventions: p – reliability of distinctions of experimental and control values; 
Symbols are the same in the next table 
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Table 2. Dynamics of plateletsʼ biochemical indices and their intravascular activity in experimental rats 
 
Registered 
parameters 
Experimental formation of AH, M±m, n=35 Experimental formation of dyslipidemia against the background of 
AH, M±m, n=35 
Control, M±m, 
n=33 
Initial stage End of AH 
formation 
Initial stage Intermediate stage End of dislipidemia 
formation against the 
background of AH 
 
cholesterol of platelets, 
mkmol/109 platelets 
0.65±0.005 0.67±0.004 
 
0.67±0.006 
 
0.71±0.008 р<0.05 0.75±0.009 р<0.01 0.66±0.004 
common phospholipids of 
platelets, umol/l /109 platelets 
0.48±0.003 0.48±0.005 0.48±0.005 
 
0.46±0.008 р<0.05 
 
0.44±0.010 р<0.05 0.49±0.006 
acylhydroperoxides of 
platelets, D233/109 platelets 
1.82±0.007 2.02±0.008 р<0.05 2.03±0.009 р<0.05 2.32±0.005 р<0.01 2.49±0.009 р<0.01 1.83±0.006 
malondialdehyde of platelets, 
nmol/109 platelets 
0.70±0.008 0.83±0.009 р<0.01 0.82±0.009 р<0.01 0.95±0.013 р<0.01 
 
1.08±0.015 р<0.01 0.69±0.007 
catalase of platelets, ME/109 
platelets 
8910.0±10.03 8100.0±12.11 р<0.01 8050.0±15.24 р<0.05 7520.0±13.02 р<0.01 7002.0±17.22 р<0.01 8890.0±16.18 
Superoxide dismutase of 
platelets, ME/109 platelets 
1650.0±5.28 1560.0±6.03 р<0.05 1570.0±6.36 р<0.05 1500.0±6.61 р<0.01 1460.0±6.92 р<0.01 1650.0±4.65 
Platelets- 
discocytes, %  
86.0±0.10 81.2±0.12 р<0.05 81.0±0.16 р<0.05 78.2±0.19 р<0.05 75.4±0.23 р<0.01 85.6±0.12 
 
Sum of platelets’  
active forms, % 
14.0±0.08 18.8±0.09 р<0.05 19.0±0.12 р<0.05 21.8±0.15 р<0.01 24.6±0.13 р<0.01 14.4±0.12 
 
Number of little  
aggregates  
(in 100 free  
platelets)  
3.0±0.08 5.6±0.09 р<0.01 5.7±0.05 р<0.01 6.9±0.06 р<0.01 8.5±0.09 р<0.01 3.1±0.09 
 
 
 
Number of medium  
and large aggregates  
(in 100 free 
platelets) 
0.18±0.005 0.49±0.007 р<0.01 0.51±0.09 р<0.01 1.22±0.011 р<0.01 1.86±0.010 р<0.01 0.16±0.004 
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Increase of platelets' activity in the given model 
should be connected not only with rise of quantity 
and activity of receptors on their surface [37]. 
The following factors are also of great 
significance: activation of phospholipase A2 and 
C, intensity of thromboxane A2 synthesis and 
factor of platelets' activation, and secretion 
increase of biologically active substances out of 
platelets. Besides, while conducting the model of 
double pathology in platelets, the yield of Ca2+ 
out of the depo was activated what rose 
actomyosin  readiness to fast reduction [38]. 
 
4. CONCLUSION  
 
Subsequent development of at first AH and then 
dyslipidemia in rats quickly weakened antioxidant 
protection of blood plasma and platelets and 
strengthened POL processes in them. 
Developing abnormalities gradually strengthened 
intravascular platelets' activity and their 
aggregative ability in experimental animals. The 
created model allowed tracking the earliest 
manifestations of strengthening of intravascular 
activity of platelets against the background of AH 
development at the beginning and then 
dyslipidemiya. Such situation is rather common 
for human beings.  
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